iiinova — where your digital self keeps evolving

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/09/2025

Real-World Myeloma Pts Remain Under-Represented in #ClinicalTrials Based on Standard Labs & Baseline Characteristics: Analysis of over 3,000 Pts from @TakedaOncology Insight - @dra_v_hungria et al. @AjaiChari - Abs 1887 #ASH19 ashpublications.org/blood/articl... #mmsm

150

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/08/2025

Lenalidomide + high-dose dexamethasone (RD) vs lenalidomide + low-dose dexamethasone (Rd) as initial therapy for newly diagnosed multiple myeloma: an open-label RCT [10/22/2009] @VincentRK et al. @TheLancetOncol ow.ly/K86r50BK0Gj #NCT00098475 #EAonc E4A03 #mmsm #caxtx #ctsm

030

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 28/07/2025

#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie ow.ly/9Z2o30oEn9T Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd

151

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 21/07/2025

030

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/07/2025

041

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 13/06/2025

Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] Walters et al. JCO PO @ascocancer.bsky.social ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc

020

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025

Heterogeneity in the expression [RNA] of GPRC5D between patients with multiple myeloma - @Phhersh et al. #ASCO25 Abst 7511 meetings.asco.org/abstracts-pr... #mmsm #PrecisionMedicine #cagenome #caxtx n=290 CD138 purified

030

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025

GEMINI-NSCLC study: Integrated longitudinal multi-omic biomarker profiling study of non-small cell lung cancer (NSCLC) patients - Palmer et al. #ASCO25 Abst TPS8114 meetings.asco.org/abstracts-pr... @TempusAI @AstraZeneca #LiquidBiopsy #ImmunoOnc #oncorad

020

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025

Circulating tumor DNA (ctDNA) dynamics in liver-limited metastatic colorectal cancer (mCRC) patients resected after first-line systemic treatment - @VStudiale et al. @AoupPisana @TempusAI #ASCO25 Abst 3544 meetings.asco.org/abstracts-pr... #crcsm #MRD #LiquidBiopsy #PrecisionMedicine

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025

Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants - @polanimd et al. #ASCO25 Abst 3572 meetings.asco.org/abstracts-pr... @TempusAI #crcsm #PrecisionMedicine

031

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025

Cohort builder in Tempus Lens: Querying a large oncology database with generative AI - West et al. @tempusAI #ASCO25 Abstract e13589 meetings.asco.org/abstracts-pr... #hemonc

000

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 23/05/2025

ImmunoDriver-1: Driver alterations (dAlts) and their immunological implications in early and metastatic non-small cell lung cancer (NSCLC) - Lee et al. @UCLAHealth @TempusAI #ASCO25 Abst 8060 meetings.asco.org/abstracts-pr... #lcsm #ImmunoOnc #PrecisionMedicine

053

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 22/05/2025

Organizing Online Health Content: Developing Hashtag Collections for Healthier Internet-Based People and Communities [Jun 28, 2019] @subatomicdoc et al. @JCOCCI_ASCO ow.ly/AxNP30p1P6g #ayacsm #bcsm #btsm #gyncsm #lcsm #mmsm #pancsm #ASCO25

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/05/2025

Germline predisposition in multiple myeloma [Dec 17, 2024] Rodrigues et al. iScience www.sciencedirect.com/science/arti... #mmsm #geneticcounselors 954 unrelated individuals w/ MM & 82 MM families

051

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 20/05/2025

Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a #CCC19 registry analysis [Mar 9, 2022] @rubinstein_md et al. @mtmdphd @COVID19nCCC @BCD_AACR ow.ly/wC8F50IgpjR #COVID19nCancer #COVID19 #bmtsm #leusm #lymsm #mmsm #mpnsm

001

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 19/05/2025

Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation [Sep 19, 2024] @KLChohan et al. @BloodJournal ashpublications.org/blood/articl... #lymphoidneoplasia #wmsm

021

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 18/05/2025

021

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 18/05/2025

011

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 18/05/2025

#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD ow.ly/aVr250BZ0dw #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 17/05/2025

Overestimation of tumor mutational burden (TMB) using algorithms compared to germline subtraction [May 26, 2019] @kaushalpar et al. @AMansfieldMD #ASCO19 Abstract 2621 ascopubs.org/doi/abs/10.1... #PrecisionMedicine #ImmunoOnc #geneticcounselors @MayoCancerCare @TempusLabs

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/05/2025

020

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/05/2025

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 14/05/2025

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

Coordinating an Oncology #PrecisionMedicine Clinic w/in an Integrated Health System: Lessons Learned in Year 1 [1/28/19] @mtmdphd Godden, Wham @antonyruggeri @mullane_michael Wilson @shamsvirani Weissman, Ramczyk, Vanderwall @JimW9200 @Aurora_Cancer @JPCRR ow.ly/VZNO30nufXz

011

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

Implementation & Utility of an Integrated Academic-Community #PrecisionMedicine Molecular Tumor Board [MTB] [Jul 5, 2017] @meburkard et al. @JCOPO_ASCO ow.ly/7Gln30dvnrx

011

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

Quantifying the Value of Molecular Tumor Board: Discordance Rec Rate & Drug Cost Avoidance [Oct 20, 2022] @mkwalters305 et al. @JCOPO_ASCO ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc Table 2

001

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

021

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

Quantifying the Value of Molecular Tumor Board: Discordance Recommendation Rate & Drug Cost Avoidance [10/20/22] @mkwalters305 @JimW9200 @antonyruggeri @mullane_michael Hunt, Wilson, Ramczyk, @mtmdphd @JCOPO_ASCO ascopubs.org/doi/abs/10.1... #PrecisionMedicine #hpeonc @Aurora_Cancer

001

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

012

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

022

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 11/05/2025

031

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 02/05/2025

020

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 02/05/2025

000

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 02/05/2025

000

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 25/04/2025

030

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 25/04/2025

020

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 09/04/2025

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO–Friends of Cancer Research Prior Therapies Work Group [Feb 9, 2021] Osarogiagbon et al. @ASCO @CancerResrch @CCR_AACR ow.ly/8P0r50Dw8Ec #ClinicalTrials #ctsm @FDAOncology

000

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 09/04/2025

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group [Feb 9, 2021] @DrAllisonMags et al. @ASCO @CancerResrch @CCR_AACR ow.ly/H6qM50Dw8uD #ClinicalTrials #ctsm @FDAOncology

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 09/04/2025

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period & Concomitant Medication Work Group [Feb 9, 2021] @DrDonaldHarvey et al. @ASCO @CancerResrch @CCR_AACR ow.ly/XnUG50Dw7UL #ClinicalTrials #ctsm @FDAOncology

000

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 09/04/2025

Continuing to Broaden Eligibility Criteria to Make #ClinicalTrials More Representative and Inclusive: ASCO–Friends of Cancer Research Joint Research Statement [Feb 9, 2021] @DrEdKim et al. @rschilsky @ASCO @CancerResrch @CCR_AACR ow.ly/jmPM50DvH0M #ctsm @FDAOncology

001

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 22/03/2025

Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML www.clinical-lymphoma-myeloma-leukemia.com/article/S215... #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx

071

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 21/03/2025

130

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 21/03/2025

021

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 21/03/2025

010

Mike Thompson, MD, PhD, FASCO @mtmdphd.bsky.social · 10/03/2025

Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19 [Nov 3, 2022] @ZiadBakouny et al. @DrChoueiri @TMWiseDraper @COVID19nCCC @JAMAOnc jamanetwork.com/journals/jam... #COVID19nCancer #CCC19 #IDonc #ImmunoOnc #NCT04354701

021